Compare AbbVie Inc (ABBV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs State Street SPDR S&P Biotech ETF — how do they compare? AbbVie Inc trades at $249.74 (market cap $441.94B), while State Street SPDR S&P Biotech ETF trades at $159.53. The key difference: AbbVie Inc pays a 2.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | XBI | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $263.58 | $164.28 |
52-Week Low | $197.38 | $86.92 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
